Video
Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCL
Author(s):
Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.
Praveen Ramakrishnan, MD, MS, assistant professor, the Department of Internal Medicine, UT Southwestern Medical Center, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).
Cell therapies, most notably CAR T-cell therapies, have had an important impact on the field of hematology, Ramakrishnan says. Most recently, the field has seen pivotal research with CAR T cells in the second-line setting for DLBCL, Ramakrishnan adds.
The phase 3 ZUMA-7 (NCT03391466) and TRANSFORM (NCT03575351) trials led to the FDA approvals of axicabtagene ciloleucel (axi-cel; Yescarta) and lisocabtagene maraleucel (liso-cel; Breyanzi) in the second-line setting of DLBCL, Ramakrishnan explains.
Overall, as more treatment options, it is important to consider become available how to sequence these treatments for patients, Ramakrishnan concludes.
